We’re excited to attend TIDES Europe from November 3rd - 5th in Amsterdam, The Netherlands. This premier event for oligonucleotide and peptide therapeutics gathers over 900 professionals across multiple disciplines to discuss the latest approaches to improving drug properties and build strategic partnerships. Connect with the Biocytogen team at booth #818 to explore our AI-powered antibody discovery platform, fully human antibody assets, target-humanized mouse models and gene editing services supporting next-generation oligonucleotide, peptides, mRNA and biologic therapeutics.
What is TIDES Europe 2026?
TIDES Europe 2026 explores advances in oligonucleotides, peptides, mRNA, and drug delivery, spanning from discovery through to commercialization. The program features new research and case studies covering molecular design, preclinical and clinical development, manufacturing, analytical methods, and regulatory strategies. Explore the latest insights into the industry with expert presentations, case studies, and interactive workshops
Event Overview
Date: November 3rd - 5th, 2026
Venue: RAI Amsterdam, Europaplein 24, 1078 GZ Amsterdam, The Netherlands
Booth: 818
Poster
Novel Fully Human Monovalent Anti-CD71 VHHs: A Highly Potent and Modular Blood-Brain Barrier Shuttle Platform for CNS Therapeutics
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
